0 3 20-	~ ខ្ល	•						•			
FORM PTG 1449 U.S. DEPARTMENT OF COMMERCI PATENT AND TRADEMARK OFFICE PADE INFORMATION DISCLOSURE STATEMENT					ATTY. DOCKET NO.: OC01617K1			APPLICATION NO.: 10/776, 988			
INFORMATION DISCLOSURE STATEMENT  BY APPLICANT  APPLICANT: Timothy J. Gu:											
	(1	Jse several sheets	e several sheets if necessary)			FILING DATE: 02/11/2004			GROUP LT		
		•	US PAT	ENT DOCU	MENTS						
EXAMIN INITIA		DOCUMENT NUMBER	DATE	NAME		CLASS				FILING DATE	
-4			11/05/1996	Rühter et al.							
	AB		02/11/1997	Rühte	er et al.	$\top$	7	$\Box$			
	AC		02/11/1997	Rühte	er et al.		7	$\Box$	•		
	AD	_ <del></del>	11/18/1997		et al.	1	T	$\Box$			
	AE		01/13/1998		et al.	<b>†</b>	1	1			
	AF		07/06/1999		ey et al.	<del> </del>	<del>                                     </del>	1-1			
- +	AG		03/21/2000		et al.	+-	_	-	<del></del>	<del> </del>	
-+	AH		08/22/2000	L	et al.	+-	<del>                                     </del>	$\vdash$			
	AI	6,191,131	02/20/2001		et al.	+	<del></del>	<del>                                     </del>		<u> </u>	
- +			07/17/2001		et al.	┿	<del></del>	<del>                                     </del>		<del> </del>	
<del>-/</del> ₩	AK		07/02/2002		nt <i>et al.</i>	+	<del> </del>	<del>   </del>		<del> </del>	
	121	<del></del>				4	<del></del>	щ.		L	
			FOREIGN PA		UMENTS						
		DOCUMENT	DATE	COUNTRY	<del>-</del>	CL	ASS	SUB		TRANS	LATIO
	j	NUMBER				1		CLA	SS	YES	NO
4	AL	DE 102 23 917 A1	11/12/2003	Ger	many	T					
$-\tau$	AM	EP 0 628 559	04/03/2002	Eui	ope						1
	AN	EP 1 334 973	08/13/2003	Eui	ope						
	AO	WO 02/22610	03/21/2002	P	CT	1					
$\neg$	AP	WO 02/40485	05/23/2002	P	CT.	1		1			
	AQ	WO 02/50079	06/27/2002	· P	CT ·	1		1			1
	/ AR	<del>-  </del>	11/06/2003		СТ	1					
<del>- 0</del>	AS	<del></del>	12/28/1995		CT	1					1
		HED DOCUMENT	TS (Including	Author Titl	o Doto Bort	ina	at Do	~~~		<u> </u>	
		HER DOCUMENT									
X	AT	(1994), 224: 771-78	6.	·	•		•				_
	ΑŪ										
·		Crystallographic Ana 3905-3927.	•								
1	AV	Mettey et al., "Aloisi	nes, a New Far	nily of CDK/GS	K-3 Inhibitors.	SAF	₹ Stu	dy, Cr	ysta	al Struct	ure in
- 1		Complex with CDK2	, Enzyme Sele	ctivity, and Cell	ular Effects", J.	. Me	d. Ch	em. (:	2003	3), 46(2)	): 222
l_		236.		· · · · · · · · · · · · · · · · · · ·							
	AW	1				'-Alk	ylami	nopyr	azol	lo[1, <b>5</b> -	
		a]pyrimidines", J. Mo				_					
	AX Senderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent										
1	- 1	Kinase Inhibitor, in F	Patients with Re	efractory Neopl	asms", <i>Journal</i>	of C	ilinica	I Onc	olog	y (Sept	embe
1998), 16(9): 2986-2999.											
AY Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Int											
		the Cyclin-Depende	n/Kinases CD0	C2, CDK2 and	CDK5", <i>Eyr. J</i> .	Bioc	hem.	(1997	7), 2	43:527-	-536.
XAMIN	NER.	/N / /\	//	DATE C	ONSIDERED						
	19V	njucia			4/17	_	51				
:XAMII	NER: I	nitial if reference cons	idered, whethe	r or not citation	is in conforma	nce	with N	<b>IPEP</b>	609	); Draw	line
		if not in conformatice	and not consid	lered. Include	copy of this for	m wi	th ne	kt con	ព៣ប	inication	ı to
oplican	N.				•						

FORM PTO	-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: OC01617K1	APPLICATION NO.: 10/776,988							
1 1815			APPLICANT:								
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  APPLICANT: Timothy J. Guzi et al.											
	(U	se several sheets if necessary)	FILING DATE: 02/22/2004	GROUP:							
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)											
AZ Bible et al., "Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various											
Ι Ψ,		Antineoplastic Agents: The Importance of Sequer 15, 1997), 57: 3375-3380.	ce of Administration", Ca	ancer Research (August							
	BA	Shiota et al., "Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin									
		Il Receptor Antagonists: Pyrazolo[1,5-α]pyrimidine Derivatives", Chem. Pharm. Bull. (1999), 47(7): 928-938.									
	ВВ	Translation of WO 03/91256, A Rising Sun Communications Ltd. Translation Product, (1-62)									
	ВС	Yasuo Makisumi, "Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted									
	<u> </u>	Pyrazolo[1,5-a]pyrimidines.", Chem. Pharm. Bull (1962), 10: 620-626.									
(	BD	Cai et al., "5-(N-Oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: Novel, Systemically									
1 1			Active and Broad Spectrum Antagonists for NMDA/glycine, AMPA, and Kainate Receptors", J.								
<del>   </del>	BE	Med. Chem. (1997), 40:3679-3686.  Bruce L. Finkelstein, "Regioselective Lithiation and Reaction of [1,2,4]Triazolo[1,5-a]pyridine and									
{		Pyrazolo[1,5-a]pyridine", J. Org. Chem., (1992), 57: 5538-5540.									
	BF	Ongkeko et al., "Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage",									
	L	Journal of Cell Science (1995), 108: 2897-2904.									
	BG	Shiota et al., "Regioselective Reactions of Organozinc Reagents with 2,4-Dichloroquinoline and									
<del></del>		5,7-Dichloropyrazolo[1,5-a]pyrimidine", <i>J. Org. Chem.</i> (1999), <b>64</b> : 453-457.									
W	BH Novinson et al., "Synthesis and Antimicrobial Activity of Some Novel Heterocycles. Azolo-αs-triazines <sup>1</sup> ", Journal of Medicinal Chemistry, (1976), 19(4): 517-520.										
	ВІ										
EXAMINER 1/1 / DATE CONSIDERED /											
10m/1/18											
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line											
through citation if not in conformance and not considered. Include copy of this form with next communication to											
applicant.											